US Pharma MarketingBeam suggests it can correct mutation; Pfizer to collaborate with Enodia
Beam Therapeutics shared Phase 1/2 data on BEAM-301 for GSDIa; Pfizer partnered with Enodia on Sec61 inhibitors for $500M+; Nurix drops NX-2127/zelebrudomide. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
Beam's first data on a rare disease gene editing therapy: Beam Therapeutics shared initial data from a Phase 1/2 trial of a base editing therapy for glycogen storage disease type Ia ...
Source: Endpoints News